News

Six Velocity Principal Investigators Co-Author Article Published in Nature Medicine

A quote from the article.

Six Velocity Principal Investigators coauthored an article recently published in Nature Medicine. The article covers the results of a Phase 2/3 trial of the Omicron BA.4/BA.5-containing bivalent mRNA-1273.222 vaccine with the ancestral Wuhan-Hu-1 mRNA-1273 as booster doses. Beyond yielding promising results, the trial has set the groundwork for swiftly addressing circulating variants as SARS-CoV-2 continues … Read more

‘New Era’ for Alzheimer’s Treatments Spur Researcher Optimism

‘New Era’ for Alzheimer’s Treatments Spur Researcher Optimism

After battling on the frontline for many years against an aggressive and elusive opponent, Michael Hemphill, MD and the Velocity team in Savannah, GA, believe we’ve entered an exciting “new era” in the fight against Alzheimer’s disease and dementia. Velocity conducts clinical trials related to disorders of the nervous system in Savannah as an embedded research … Read more

Velocity Syracuse Team Advances Important Alzheimer’s Trials 

Velocity Syracuse Team Advances Important Alzheimer’s Trials

Alzheimer’s is currently ranked as the seventh leading cause of death in the United States and is the most common cause of dementia among older adults.  Alzheimer’s disease, a cruel and pernicious affliction, is a brain disorder that slowly destroys memory, thinking skills, and eventually, the ability to carry out even the most simple and … Read more

Velocity Launches Vaccine Council to Accelerate Research Excellence (CARE)

Velocity Launches Vaccine Council to Accelerate Research Excellence (CARE)

Velocity has introduced the Vaccine Council to Accelerate Research Excellence (CARE). This council will bring world-class operational, patient recruitment, and trial conduct oversight to all Velocity sites conducting vaccine studies in the U.S. and Europe. Led by some of the world’s top vaccine Principal Investigators, including Brandon Essink, MD, CPI, the Vaccine CARE Council will … Read more

Julio Rosenstock, MD Co-Authored an Article Published in NEJM

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

Another positive step in obesity research: Julio Rosenstock, MD, is a co-author of an article now featured on The New England Journal of Medicine homepage, and in the publication’s weekend email briefing. From the article, Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity: “At week 26, the mean change from baseline in body … Read more

Velocity Acquires Site in Berlin, Fourth in Germany

What do you get when you have a business economist with nursing experience? In this case, it’s one of the founding members of a clinical trials site in Berlin, Germany, which has become the latest member of Velocity’s integrated site network in Europe. Dominic Clavell, European General Manager, explained, “This is Velocity’s fourth site acquisition … Read more

Velocity Ranks 543 on the Inc. 5000 List of Fastest-Growing Private Companies in the U.S.

Inc. magazine ranked Velocity Clinical Research 543 on its annual Inc. 5000 list, the most prestigious ranking of the nation’s fastest-growing private companies. Headquartered in Durham, NC, Velocity is the world’s leading integrated site organization with 80 sites worldwide. This is Velocity’s first recognition on the list.   Paul Evans, President and CEO of Velocity Clinical … Read more

Velocity Collaborates With Merck to Improve Diversity in Clinical Trials

Velocity is collaborating with Merck to explore a new way to engage communities about clinical research. Starting this month the Velocity team members are conducting a tour of several Southern California cities, using Merck’s iLab53, a state-of-the-art, modular 39-foot mobile research unit to reach underserved communities. At each stop, the mobile research unit will serve … Read more